Objectives & outcomes:
- Unimodal analytics, prognostics biomarkers, and signature profiles for cohorts and patients
- Custom models based on Multimodal signature (MMMO_Sig) and multimodal model prognostic risk score (MMMO_PRS)
- ACCUITIVE’s MMMO_PRS model is a novel and unique approach that confers flexibility to clinicians for better patient care in real-world settings where the availability of omics data for individual patients is non-uniform. The model has the distinct advantage of accounting for missing data
- Flexibility to apply MMMO_Sig and MMMO_PRS based on the availability of data for respective modalities for a cohort (single and/or combinations)
- Precision prescription prioritization simulation outcome for individual patients to assist relative ranking of available therapies based on patient’s omics data to assist clinicians
Salient features:
- Supports clinical, radiomics, genomics, transcriptomics, proteomics, and immunomics data analysis
- User-friendly, interactive, and insightful graphical depictions of the results, such as pie charts, survival plots, volcano plots, circular heatmaps, upset plots, etc.
- Standard survival outcomes in terms of OS, 5-year, and 10-year survival.
- ACCUITIVE is an enterprise solution with a robust framework that can be applied to other solid tumors.
Demo use case: Breast cancer
Data source: The Cancer Genome Atlas
Business model: Contract services
Please write to us:
for details & we will be happy to discuss: accuitivebd@citadelpm.io
